Ileal Bile Acid Transporter Inhibitor Improves Hepatic Steatosis by Ameliorating Gut Microbiota Dysbiosis in NAFLD Model Mice

ABSTRACT Nonalcoholic fatty liver disease (NAFLD), characterized by excessive fat deposition in the liver unrelated to alcohol consumption, is highly prevalent worldwide. However, effective therapeutic agents approved for NAFLD treatment are lacking. An ileal bile acid transporter inhibitor (IBATi),...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Masahiro Matsui, Shinya Fukunishi, Takashi Nakano, Takaaki Ueno, Kazuhide Higuchi, Akira Asai
Formato:	article
Lenguaje:	EN
Publicado:	American Society for Microbiology 2021
Materias:	nonalcoholic fatty liver disease ileal bile acid transporter inhibitor gut microbiome nonalcoholic steatohepatitis Microbiology QR1-502
Acceso en línea:	https://doaj.org/article/9a0e2589159b4a369b5a6805e28b8614
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:9a0e2589159b4a369b5a6805e28b8614
record_format	dspace
spelling	oai:doaj.org-article:9a0e2589159b4a369b5a6805e28b86142021-11-10T18:37:51ZIleal Bile Acid Transporter Inhibitor Improves Hepatic Steatosis by Ameliorating Gut Microbiota Dysbiosis in NAFLD Model Mice10.1128/mBio.01155-212150-7511https://doaj.org/article/9a0e2589159b4a369b5a6805e28b86142021-08-01T00:00:00Zhttps://journals.asm.org/doi/10.1128/mBio.01155-21https://doaj.org/toc/2150-7511ABSTRACT Nonalcoholic fatty liver disease (NAFLD), characterized by excessive fat deposition in the liver unrelated to alcohol consumption, is highly prevalent worldwide. However, effective therapeutic agents approved for NAFLD treatment are lacking. An ileal bile acid transporter inhibitor (IBATi), which represents a new mode of treatment of chronic idiopathic constipation, leads to increased delivery of bile acids to the colon. We investigated the effect of IBATi against NAFLD through modification of the gut microbiota in mice. IBATi treatment significantly suppressed body weight gain, liver dysfunction, and serum low-density lipoprotein levels and significantly decreased NAFLD activity scores in high-fat diet (HFD) mice. Treatment with IBATi ameliorated the decreased hepatic cholesterol 7-a-monooxygenase (Cyp7a1) and increased ileal fibroblast growth factor 15 (Fgf15) mRNA expression in HFD mice. Further, IBATi treatment changed the α-diversity in the gut microbiota reduced by HFD, which was analyzed in feces using 16S rRNA sequencing. To establish the mechanism underlying improvement in NAFLD induced by IBATi, we recolonized antibiotic solution-treated mice by fecal microbiome transplantation (FMT) using stool from HFD or HFD plus IBATi mice. This is the first report that fecally transplanted gut microbiota from HFD plus IBATi mice prevented hepatic steatosis caused by HFD. In conclusion, IBATi improved hepatic steatosis by ameliorating gut microbiota dysbiosis in NAFLD model mice, suggesting a potential therapeutic agent for NAFLD treatment. IMPORTANCE NAFLD is an increasingly recognized condition that may progress to liver cirrhosis and hepatocellular carcinoma, and community surveys have assessed that the prevalence is 14 to 32% worldwide. The first line of treatment for NAFLD is lifestyle modification to achieve weight reduction, particularly through diet and exercise. However, weight reduction is difficult to achieve and maintain, and pharmacological agents approved for the treatment of NAFLD are lacking. This study investigated the influence of the gut microbiota and the effect of an IBATi on NAFLD using a murine model. Treatment with IBATi significantly improved NAFLD in HFD mice. Further, fecal microbiome transplantation using stool from HFD plus IBATi mice prevented hepatic steatosis caused by HFD. Our study makes a significant contribution to the literature because the study findings suggest a potential treatment strategy for NAFLD patients by ameliorating gut microbiota dysbiosis.Masahiro MatsuiShinya FukunishiTakashi NakanoTakaaki UenoKazuhide HiguchiAkira AsaiAmerican Society for Microbiologyarticlenonalcoholic fatty liver diseaseileal bile acid transporter inhibitorgut microbiomenonalcoholic steatohepatitisMicrobiologyQR1-502ENmBio, Vol 12, Iss 4 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	nonalcoholic fatty liver disease ileal bile acid transporter inhibitor gut microbiome nonalcoholic steatohepatitis Microbiology QR1-502
spellingShingle	nonalcoholic fatty liver disease ileal bile acid transporter inhibitor gut microbiome nonalcoholic steatohepatitis Microbiology QR1-502 Masahiro Matsui Shinya Fukunishi Takashi Nakano Takaaki Ueno Kazuhide Higuchi Akira Asai Ileal Bile Acid Transporter Inhibitor Improves Hepatic Steatosis by Ameliorating Gut Microbiota Dysbiosis in NAFLD Model Mice
description	ABSTRACT Nonalcoholic fatty liver disease (NAFLD), characterized by excessive fat deposition in the liver unrelated to alcohol consumption, is highly prevalent worldwide. However, effective therapeutic agents approved for NAFLD treatment are lacking. An ileal bile acid transporter inhibitor (IBATi), which represents a new mode of treatment of chronic idiopathic constipation, leads to increased delivery of bile acids to the colon. We investigated the effect of IBATi against NAFLD through modification of the gut microbiota in mice. IBATi treatment significantly suppressed body weight gain, liver dysfunction, and serum low-density lipoprotein levels and significantly decreased NAFLD activity scores in high-fat diet (HFD) mice. Treatment with IBATi ameliorated the decreased hepatic cholesterol 7-a-monooxygenase (Cyp7a1) and increased ileal fibroblast growth factor 15 (Fgf15) mRNA expression in HFD mice. Further, IBATi treatment changed the α-diversity in the gut microbiota reduced by HFD, which was analyzed in feces using 16S rRNA sequencing. To establish the mechanism underlying improvement in NAFLD induced by IBATi, we recolonized antibiotic solution-treated mice by fecal microbiome transplantation (FMT) using stool from HFD or HFD plus IBATi mice. This is the first report that fecally transplanted gut microbiota from HFD plus IBATi mice prevented hepatic steatosis caused by HFD. In conclusion, IBATi improved hepatic steatosis by ameliorating gut microbiota dysbiosis in NAFLD model mice, suggesting a potential therapeutic agent for NAFLD treatment. IMPORTANCE NAFLD is an increasingly recognized condition that may progress to liver cirrhosis and hepatocellular carcinoma, and community surveys have assessed that the prevalence is 14 to 32% worldwide. The first line of treatment for NAFLD is lifestyle modification to achieve weight reduction, particularly through diet and exercise. However, weight reduction is difficult to achieve and maintain, and pharmacological agents approved for the treatment of NAFLD are lacking. This study investigated the influence of the gut microbiota and the effect of an IBATi on NAFLD using a murine model. Treatment with IBATi significantly improved NAFLD in HFD mice. Further, fecal microbiome transplantation using stool from HFD plus IBATi mice prevented hepatic steatosis caused by HFD. Our study makes a significant contribution to the literature because the study findings suggest a potential treatment strategy for NAFLD patients by ameliorating gut microbiota dysbiosis.
format	article
author	Masahiro Matsui Shinya Fukunishi Takashi Nakano Takaaki Ueno Kazuhide Higuchi Akira Asai
author_facet	Masahiro Matsui Shinya Fukunishi Takashi Nakano Takaaki Ueno Kazuhide Higuchi Akira Asai
author_sort	Masahiro Matsui
title	Ileal Bile Acid Transporter Inhibitor Improves Hepatic Steatosis by Ameliorating Gut Microbiota Dysbiosis in NAFLD Model Mice
title_short	Ileal Bile Acid Transporter Inhibitor Improves Hepatic Steatosis by Ameliorating Gut Microbiota Dysbiosis in NAFLD Model Mice
title_full	Ileal Bile Acid Transporter Inhibitor Improves Hepatic Steatosis by Ameliorating Gut Microbiota Dysbiosis in NAFLD Model Mice
title_fullStr	Ileal Bile Acid Transporter Inhibitor Improves Hepatic Steatosis by Ameliorating Gut Microbiota Dysbiosis in NAFLD Model Mice
title_full_unstemmed	Ileal Bile Acid Transporter Inhibitor Improves Hepatic Steatosis by Ameliorating Gut Microbiota Dysbiosis in NAFLD Model Mice
title_sort	ileal bile acid transporter inhibitor improves hepatic steatosis by ameliorating gut microbiota dysbiosis in nafld model mice
publisher	American Society for Microbiology
publishDate	2021
url	https://doaj.org/article/9a0e2589159b4a369b5a6805e28b8614
work_keys_str_mv	AT masahiromatsui ilealbileacidtransporterinhibitorimproveshepaticsteatosisbyamelioratinggutmicrobiotadysbiosisinnafldmodelmice AT shinyafukunishi ilealbileacidtransporterinhibitorimproveshepaticsteatosisbyamelioratinggutmicrobiotadysbiosisinnafldmodelmice AT takashinakano ilealbileacidtransporterinhibitorimproveshepaticsteatosisbyamelioratinggutmicrobiotadysbiosisinnafldmodelmice AT takaakiueno ilealbileacidtransporterinhibitorimproveshepaticsteatosisbyamelioratinggutmicrobiotadysbiosisinnafldmodelmice AT kazuhidehiguchi ilealbileacidtransporterinhibitorimproveshepaticsteatosisbyamelioratinggutmicrobiotadysbiosisinnafldmodelmice AT akiraasai ilealbileacidtransporterinhibitorimproveshepaticsteatosisbyamelioratinggutmicrobiotadysbiosisinnafldmodelmice
_version_	1718439800153833472

Ileal Bile Acid Transporter Inhibitor Improves Hepatic Steatosis by Ameliorating Gut Microbiota Dysbiosis in NAFLD Model Mice

Ejemplares similares